{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:52:44Z","timestamp":1767999164773,"version":"3.49.0"},"publisher-location":"Cham","reference-count":144,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319717784","type":"print"},{"value":"9783319717791","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-71779-1_19","type":"book-chapter","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T04:51:01Z","timestamp":1518151861000},"page":"369-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacological Therapies for Machado-Joseph Disease"],"prefix":"10.1007","author":[{"given":"Sara","family":"Duarte-Silva","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia","family":"Maciel","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","unstructured":"Paulson H (2012) Machado-Joseph disease\/spinocerebellar ataxia type 3. Handb Clin Neurol 103:437\u2013449","DOI":"10.1016\/B978-0-444-51892-7.00027-9"},{"issue":"1","key":"19_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-6-35","volume":"6","author":"Concei\u00e7\u00e3o Bettencourt","year":"2011","unstructured":"Bettencourt C, Lima M (2011) Machado-Joseph disease: from first descriptions to new perspectives. Orphanet J Rare Dis 6:35","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"19_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pneurobio.2011.06.007","volume":"95","author":"CA Matos","year":"2011","unstructured":"Matos CA, de Macedo-Ribeiro S, Carvalho AL (2011) Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog Neurobiol 95(1):26\u201348","journal-title":"Prog Neurobiol"},{"issue":"5","key":"19_CR4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(04)00737-9","volume":"3","author":"L Schols","year":"2004","unstructured":"Schols L, Bauer P, Schmidt T, Schulte T, Riess O (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3(5):291\u2013304","journal-title":"Lancet Neurol"},{"issue":"2","key":"19_CR5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12035-012-8316-3","volume":"46","author":"PM Switonski","year":"2012","unstructured":"Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M (2012) Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol 46(2):430\u2013466","journal-title":"Mol Neurobiol"},{"issue":"6","key":"19_CR6","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1471-4159.2009.06302.x","volume":"110","author":"PO Bauer","year":"2009","unstructured":"Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110(6):1737\u20131765","journal-title":"J Neurochem"},{"issue":"5","key":"19_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1517\/21678707.2015.1025747","volume":"3","author":"JAM Saute","year":"2015","unstructured":"Saute JAM, Jardim LB (2015) Machado Joseph disease: clinical and genetic aspects, and current treatment. Expert Opin Orphan Drugs 3(5):517\u2013535","journal-title":"Expert Opin Orphan Drugs"},{"issue":"3","key":"19_CR8","first-page":"203","volume":"29","author":"P Coutinho","year":"1981","unstructured":"Coutinho P, Sequeiros J (1981) Clinical, genetic and pathological aspects of Machado-Joseph disease. J Genet Hum 29(3):203\u2013209","journal-title":"J Genet Hum"},{"issue":"2","key":"19_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","volume":"7","author":"O Riess","year":"2008","unstructured":"Riess O, Rub U, Pastore A, Bauer P, Schols L (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7(2):125\u2013137","journal-title":"Cerebellum"},{"issue":"3","key":"19_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870070302","volume":"7","author":"RN Rosenberg","year":"1992","unstructured":"Rosenberg RN (1992) Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 7(3):193\u2013203","journal-title":"Mov Disord"},{"issue":"2","key":"19_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WCO.0b013e3282f7673d","volume":"21","author":"U Rub","year":"2008","unstructured":"Rub U, Brunt ER, Deller T (2008) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21(2):111\u2013116","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"19_CR12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archneur.65.4.525","volume":"65","author":"MC Franca Jr","year":"2008","unstructured":"Franca MC Jr, D\u2019Abreu A, Nucci A, Lopes-Cendes I (2008) Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 65(4):525\u2013529","journal-title":"Arch Neurol"},{"issue":"9","key":"19_CR13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/mds.22122","volume":"23","author":"JH Friedman","year":"2008","unstructured":"Friedman JH, Amick MM (2008) Fatigue and daytime somnolence in Machado Joseph disease (spinocerebellar ataxia type 3). Mov Disord 23(9):1323\u20131324","journal-title":"Mov Disord"},{"issue":"6","key":"19_CR14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/WNL.51.6.1603","volume":"51","author":"L Schols","year":"1998","unstructured":"Schols L, Haan J, Riess O, Amoiridis G, Przuntek H (1998) Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 51(6):1603\u20131607","journal-title":"Neurology"},{"issue":"11","key":"19_CR15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/archneur.61.11.1757","volume":"61","author":"Y Kawai","year":"2004","unstructured":"Kawai Y, Takeda A, Abe Y, Washimi Y, Tanaka F, Sobue G (2004) Cognitive impairments in Machado-Joseph disease. Arch Neurol 61(11):1757\u20131760","journal-title":"Arch Neurol"},{"issue":"7","key":"19_CR16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00415-015-7807-3","volume":"262","author":"UC Silva","year":"2015","unstructured":"Silva UC, Marques W Jr, Lourenco CM, Hallak JE, Osorio FL (2015) Psychiatric disorders, spinocerebellar ataxia type 3 and CAG expansion. J Neurol 262(7):1777\u20131779","journal-title":"J Neurol"},{"issue":"2","key":"19_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","volume":"19","author":"HL Paulson","year":"1997","unstructured":"Paulson HL, Perez MK, Trottier Y, et al (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19(2):333\u2013344","journal-title":"Neuron"},{"issue":"4","key":"19_CR18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1750-3639.1998.tb00193.x","volume":"8","author":"T Schmidt","year":"1998","unstructured":"Schmidt T, Landwehrmeyer GB, Schmitt I, et al (1998) An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 8(4):669\u2013679","journal-title":"Brain Pathol"},{"issue":"2","key":"19_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.brainresrev.2006.08.003","volume":"53","author":"U Rub","year":"2007","unstructured":"Rub U, Seidel K, Ozerden I, et al (2007) Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev 53(2):235\u2013249","journal-title":"Brain Res Rev"},{"issue":"6","key":"19_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2990.2004.00583.x","volume":"30","author":"M Yamada","year":"2004","unstructured":"Yamada M, Tan CF, Inenaga C, Tsuji S, Takahashi H (2004) Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases. Neuropathol Appl Neurobiol 30(6):665\u2013675","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"19_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00401-010-0717-7","volume":"120","author":"K Seidel","year":"2010","unstructured":"Seidel K, den Dunnen WF, Schultz C, et al (2010) Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 120(4):449\u2013460","journal-title":"Acta Neuropathol"},{"issue":"7","key":"19_CR22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1212\/WNL.28.7.703","volume":"28","author":"P Coutinho","year":"1978","unstructured":"Coutinho P, Andrade C (1978) Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 28(7):703\u2013709","journal-title":"Neurology"},{"issue":"3","key":"19_CR23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1212\/WNL.30.3.319","volume":"30","author":"L. Lima","year":"1980","unstructured":"Lima L, Coutinho P (1980) Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azoren Portuguese family. Neurology 30(3):319\u2013322","journal-title":"Neurology"},{"key":"19_CR24","unstructured":"Paulson H (1993). Spinocerebellar ataxia type 3. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews(R). Seattle, WA"},{"issue":"11","key":"19_CR25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/archneur.58.11.1821","volume":"58","author":"P Maciel","year":"2001","unstructured":"Maciel P, Costa MC, Ferro A, et al (2001) Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 58(11):1821\u20131827","journal-title":"Arch Neurol"},{"issue":"1","key":"19_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10897-011-9383-8","volume":"21","author":"Caroline Santa Maria Rodrigues","year":"2011","unstructured":"Rodrigues CS, de Oliveira VZ, Camargo G, et al (2012) Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing. J genet couns 21(1):101\u2013112","journal-title":"Journal of Genetic Counseling"},{"issue":"5","key":"19_CR27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1545968311425918","volume":"26","author":"Ichiro Miyai","year":"2011","unstructured":"Miyai I, Ito M, Hattori N, et al (2012) Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair 26(5):515\u2013522","journal-title":"Neurorehabilitation and Neural Repair"},{"issue":"6","key":"19_CR28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1545968314562108","volume":"29","author":"Martina Svensson","year":"2014","unstructured":"Svensson M, Lexell J, Deierborg T (2015) Effects of physical exercise on neuroinflammation, neuroplasticity, neurodegeneration, and behavior: what we can learn from animal models in clinical settings. Neurorehabil Neural Repair 29(6):577\u2013589","journal-title":"Neurorehabilitation and Neural Repair"},{"issue":"6","key":"19_CR29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1590\/S0100-879X2010005000009","volume":"43","author":"RC Silva","year":"2010","unstructured":"Silva RC, Saute JA, Silva AC, Coutinho AC, Saraiva-Pereira ML, Jardim LB (2010) Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas\/Sociedade Brasileira de Biofisica [et al] 43(6):537\u2013542","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"19_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000096276","volume":"10","author":"CR Cecchin","year":"2007","unstructured":"Cecchin CR, Pires AP, Rieder CR, et al (2007) Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives. Commun Genet 10(1):19\u201326","journal-title":"Commun Genet"},{"issue":"944","key":"19_CR31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/pgmj.2003.015297","volume":"80","author":"R Nandagopal","year":"2004","unstructured":"Nandagopal R, Moorthy SG (2004) Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J 80(944):363\u2013365","journal-title":"Postgrad Med J"},{"issue":"980","key":"19_CR32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","volume":"83","author":"B Thanvi","year":"2007","unstructured":"Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83(980):384\u2013388","journal-title":"Postgrad Med J"},{"issue":"1","key":"19_CR33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.parkreldis.2009.08.012","volume":"16","author":"A D\u2019Abreu","year":"2010","unstructured":"D\u2019Abreu A, Franca MC Jr, Paulson HL, Lopes-Cendes I (2010) Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord 16(1):2\u20137","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"19_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13041-015-0160-8","volume":"8","author":"WJ Szlachcic","year":"2015","unstructured":"Szlachcic WJ, Switonski PM, Kurkowiak M, Wiatr K, Figiel M (2015) Mouse polyQ database: a new online resource for research using mouse models of neurodegenerative diseases. Mol Brain 8(1):69","journal-title":"Mol Brain"},{"issue":"2","key":"19_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13311-012-0117-x","volume":"3","author":"VF Colomer Gould","year":"2012","unstructured":"Colomer Gould VF (2012) Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 9(2):285\u2013296","journal-title":"Neurotherapeutics"},{"issue":"5","key":"19_CR36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1568009033481787","volume":"3","author":"L Whitesell","year":"2003","unstructured":"Whitesell L, Bagatell R, Falsey R (2003) The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3(5):349\u2013358","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"19_CR37","first-page":"3312","volume":"6","author":"R Bagatell","year":"2000","unstructured":"Bagatell R, Paine-Murrieta GD, Taylor CW, et al (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6(8):3312\u20133318","journal-title":"Clin Cancer Res"},{"issue":"38","key":"19_CR38","doi-asserted-by":"crossref","first-page":"26188","DOI":"10.1074\/jbc.M710521200","volume":"283","author":"N Fujikake","year":"2008","unstructured":"Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283(38):26188\u201326197","journal-title":"J Biol Chem"},{"issue":"5","key":"19_CR39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/hmg\/ddn419","volume":"18","author":"Keisuke Tokui","year":"2008","unstructured":"Tokui K, Adachi H, Waza M, et al (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 18(5):898\u2013910","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"19_CR40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1298","volume":"11","author":"M Waza","year":"2005","unstructured":"Waza M, Adachi H, Katsuno M, et al (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11(10):1088\u20131095","journal-title":"Nat Med"},{"issue":"11","key":"19_CR41","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/hmg\/ddl110","volume":"15","author":"M Thomas","year":"2006","unstructured":"Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, Lieberman AP (2006) Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum Mol Genet 15(11):1876\u20131883","journal-title":"Hum Mol Genet"},{"issue":"2","key":"19_CR42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13311-013-0255-9","volume":"11","author":"Anabela Silva-Fernandes","year":"2014","unstructured":"Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, et al (2014) Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurother: j Am Soc Exp NeuroTher 11(2):433\u2013449","journal-title":"Neurotherapeutics"},{"issue":"3","key":"19_CR43","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","volume":"1823","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823(3):742\u2013755","journal-title":"Biochim Biophys Acta"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-015-0009-8","volume":"10","author":"M Cano-Espinel del","year":"2015","unstructured":"del Cano-Espinel M, Acebes JR, Sanchez D, Ganfornina MD (2015) Lazarillo-related Lipocalins confer long-term protection against type I Spinocerebellar ataxia degeneration contributing to optimize selective autophagy. Mol Neurodegeneration 10:11","journal-title":"Mol Neurodegeneration"},{"issue":"3","key":"19_CR45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/cdd.2014.151","volume":"22","author":"FM Menzies","year":"2015","unstructured":"Menzies FM, Garcia-Arencibia M, Imarisio S, et al (2015) Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. Cell Death Differ 22(3):433\u2013444","journal-title":"Cell Death Differ"},{"key":"19_CR46","unstructured":"Tsunemi T, Ashe TD, Morrison BE, et al (2012) PGC-1alpha rescues Huntington\u2019s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 4(142):142\u2013197"},{"issue":"2","key":"19_CR47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1471-4159.2011.07435.x","volume":"119","author":"A Roscic","year":"2011","unstructured":"Roscic A, Baldo B, Crochemore C, Marcellin D, Paganetti P (2011) Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J Neurochem 119(2):398\u2013407","journal-title":"J Neurochem"},{"issue":"Pt 1","key":"19_CR48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awp292","volume":"133","author":"FM Menzies","year":"2010","unstructured":"Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain : J neurol 133(Pt 1):93\u2013104","journal-title":"Brain : J neurol"},{"issue":"2","key":"19_CR49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/hmg\/ddm294","volume":"17","author":"S Sarkar","year":"2008","unstructured":"Sarkar S, Krishna G, Imarisio S, Saiki S, O\u2019Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington\u2019s disease using lithium and rapamycin. Hum Mol Genet 17(2):170\u2013178","journal-title":"Hum Mol Genet"},{"key":"19_CR50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0070-2153(06)76003-3","volume":"76","author":"A Williams","year":"2006","unstructured":"Williams A, Jahreiss L, Sarkar S, et al (2006) Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 76:89\u2013101","journal-title":"Curr Top Dev Biol"},{"issue":"9","key":"19_CR51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","volume":"11","author":"B Ravikumar","year":"2002","unstructured":"Ravikumar B, Duden R, Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11(9):1107\u20131117","journal-title":"Hum Mol Genet"},{"issue":"6","key":"19_CR52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z, et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585\u2013595","journal-title":"Nat Genet"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mcn.2015.01.003","volume":"66","author":"Maria Xilouri","year":"2015","unstructured":"Xilouri M, Stefanis L (2015) Chaperone mediated autophagy to the rescue: a new-fangled target for the treatment of neurodegenerative diseases. Mol Cell Neurosci 66(Pt A):29\u201336","journal-title":"Molecular and Cellular Neuroscience"},{"issue":"1","key":"19_CR54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1172\/JCI73944","volume":"125","author":"RA Frake","year":"2015","unstructured":"Frake RA, Ricketts T, Menzies FM, Rubinsztein DC (2015) Autophagy and neurodegeneration. J Clin Invest 125(1):65\u201374","journal-title":"J Clin Invest"},{"issue":"2","key":"19_CR55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2011.200","volume":"8","author":"H Harris","year":"2012","unstructured":"Harris H, Rubinsztein DC (2012) Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 8(2):108\u2013117","journal-title":"Nat Rev Neurol"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mcn.2015.03.010","volume":"66","author":"Constanza J. Cortes","year":"2015","unstructured":"Cortes CJ, La Spada AR (2015) Autophagy in polyglutamine disease: imposing order on disorder or contributing to the chaos? Mol Cell Neurosci 66(Pt A): 53\u201361","journal-title":"Molecular and Cellular Neuroscience"},{"issue":"28","key":"19_CR57","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1523\/JNEUROSCI.4540-06.2007","volume":"27","author":"U Bichelmeier","year":"2007","unstructured":"Bichelmeier U, Schmidt T, Hubener J, et al (2007) Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci: Official J Soc Neurosci 27(28):7418\u20137428","journal-title":"J Neurosci: Official J Soc Neurosci"},{"issue":"Pt 5","key":"19_CR58","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awr047","volume":"134","author":"I Nascimento-Ferreira","year":"2011","unstructured":"Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, et al (2011) Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain: J neurol 134(Pt 5):1400\u20131415","journal-title":"Brain: J neurol"},{"issue":"6","key":"19_CR59","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12311-014-0589-9","volume":"13","author":"S Duarte-Silva","year":"2014","unstructured":"Duarte-Silva S, Neves-Carvalho A, Soares-Cunha C, et al (2014) Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease. Cerebellum 13(6):713\u2013727","journal-title":"Cerebellum"},{"issue":"4","key":"19_CR60","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","volume":"29","author":"JA Saute","year":"2014","unstructured":"Saute JA, de Castilhos RM, Monte TL, et al (2014) A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 29(4):568\u2013573","journal-title":"Mov Disord"},{"key":"19_CR61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neuroscience.2015.11.030","volume":"313","author":"S. Duarte-Silva","year":"2016","unstructured":"Duarte-Silva S, Silva-Fernandes A, Neves-Carvalho A, Soares-Cunha C, Teixeira-Castro A, Maciel P (2016) Combined therapy with m-TOR-dependent and -independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease. Neuroscience 313:162\u2013173","journal-title":"Neuroscience"},{"issue":"1","key":"19_CR62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2008.03.011","volume":"31","author":"AH Chou","year":"2008","unstructured":"Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL (2008) Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 31(1):89\u2013101","journal-title":"Neurobiol Dis"},{"key":"19_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.01.006","volume":"70","author":"Hung-Li Wang","year":"2013","unstructured":"Wang HL, Hu SH, Chou AH, Wang SS, Weng YH, Yeh TH (2013) H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse. Neuropharmacology 70:1\u201311","journal-title":"Neuropharmacology"},{"issue":"5","key":"19_CR64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","volume":"4","author":"BK Mueller","year":"2005","unstructured":"Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4(5):387\u2013398","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"19_CR65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","volume":"36","author":"M Li","year":"2009","unstructured":"Li M, Huang Y, Ma AA, Lin E, Diamond MI (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice. Neurobiol Dis 36(3):413\u2013420","journal-title":"Neurobiol Dis"},{"issue":"9","key":"19_CR66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2176\/nmc.46.421","volume":"46","author":"J Zhao","year":"2006","unstructured":"Zhao J, Zhou D, Guo J, et al (2006) Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir 46(9):421\u2013428","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"19_CR67","doi-asserted-by":"crossref","unstructured":"Ahmed LA, Darwish HA, Abdelsalam RM, Amin HA (2015) Role of Rho kinase inhibition in the protective effect of Fasudil and Simvastatin against 3-Nitropropionic acid-induced striatal neurodegeneration and mitochondrial dysfunction in Rats. Mol Neurobiol","DOI":"10.1007\/s12035-015-9303-2"},{"issue":"4","key":"19_CR68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mc.20488","volume":"48","author":"Y Lin","year":"2009","unstructured":"Lin Y, Hubert L Jr, Wilson JH (2009) Transcription destabilizes triplet repeats. Mol Carcinog 48(4):350\u2013361","journal-title":"Mol Carcinog"},{"issue":"7","key":"19_CR69","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00018-003-3013-z","volume":"60","author":"H Okazawa","year":"2003","unstructured":"Okazawa H (2003) Polyglutamine diseases: a transcription disorder? Cell Mol Life Sci 60(7):1427\u20131439","journal-title":"Cell Mol Life Sci"},{"issue":"14","key":"19_CR70","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","volume":"9","author":"A McCampbell","year":"2000","unstructured":"McCampbell A, Taylor JP, Taye AA, et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9(14):2197\u20132202","journal-title":"Hum Mol Genet"},{"issue":"12","key":"19_CR71","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.1087503","volume":"17","author":"JP Taylor","year":"2003","unstructured":"Taylor JP, Taye AA, Campbell C, Kazemi-Esfarjani P, Fischbeck KH, Min KT (2003) Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev 17(12):1463\u20131468","journal-title":"Genes Dev"},{"issue":"47","key":"19_CR72","doi-asserted-by":"crossref","first-page":"45004","DOI":"10.1074\/jbc.M205259200","volume":"277","author":"F Li","year":"2002","unstructured":"Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277(47):45004\u201345012","journal-title":"J Biol Chem"},{"issue":"5","key":"19_CR73","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","volume":"22","author":"SH Li","year":"2002","unstructured":"Li SH, Cheng AL, Zhou H, et al (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22(5):1277\u20131287","journal-title":"Mol Cell Biol"},{"issue":"5","key":"19_CR74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4161\/nucl.21481","volume":"3","author":"D Cohen-Carmon","year":"2012","unstructured":"Cohen-Carmon D, Meshorer E (2012) Polyglutamine (polyQ) disorders: the chromatin connection. Nucleus 3(5):433\u2013441","journal-title":"Nucleus"},{"issue":"48","key":"19_CR75","doi-asserted-by":"crossref","first-page":"44889","DOI":"10.1074\/jbc.M106575200","volume":"276","author":"Y Chai","year":"2001","unstructured":"Chai Y, Wu L, Griffin JD, Paulson HL (2001) The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem 276(48):44889\u201344897","journal-title":"J Biol Chem"},{"issue":"5576","key":"19_CR76","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","volume":"296","author":"AW Dunah","year":"2002","unstructured":"Dunah AW, Jeong H, Griffin A, et al (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease. Science 296(5576):2238\u20132243","journal-title":"Science"},{"issue":"5634","key":"19_CR77","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1126\/science.1086887","volume":"301","author":"SI Grewal","year":"2003","unstructured":"Grewal SI, Moazed D (2003) Heterochromatin and epigenetic control of gene expression. Science 301(5634):798\u2013802","journal-title":"Science"},{"issue":"2","key":"19_CR78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","volume":"41","author":"AH Chou","year":"2011","unstructured":"Chou AH, Chen SY, Yeh TH, Weng YH, Wang HL (2011) HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 41(2):481\u2013488","journal-title":"Neurobiol Dis"},{"issue":"10","key":"19_CR79","doi-asserted-by":"crossref","first-page":"e0141610","DOI":"10.1371\/journal.pone.0141610","volume":"10","author":"Sofia Esteves","year":"2015","unstructured":"Esteves S, Duarte-Silva S, Naia L, et al (2015) Limited effect of chronic valproic acid treatment in a mouse model of Machado-Joseph disease. PloS one 10(10):e0141610","journal-title":"PLOS ONE"},{"issue":"2","key":"19_CR80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0896-6273(03)00366-0","volume":"39","author":"TS Tang","year":"2003","unstructured":"Tang TS, Tu H, Chan EY, et al (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39(2):227\u2013239","journal-title":"Neuron"},{"issue":"7","key":"19_CR81","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1073\/pnas.0409402102","volume":"102","author":"TS Tang","year":"2005","unstructured":"Tang TS, Slow E, Lupu V, et al (2005) Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington\u2019s disease. Proc Natl Acad Sci USA 102(7):2602\u20132607","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"19_CR82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neulet.2006.08.036","volume":"407","author":"J Wu","year":"2006","unstructured":"Wu J, Tang T, Bezprozvanny I (2006) Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington\u2019s disease. Neurosci Lett 407(3):219\u2013223","journal-title":"Neurosci Lett"},{"issue":"9","key":"19_CR83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/hmg\/11.9.1075","volume":"11","author":"C. K. Cemal","year":"2002","unstructured":"Cemal CK, Carroll CJ, Lawrence L, et al (2002) YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum mol genet 11(9):1075\u20131094","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"19_CR84","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","volume":"59","author":"T Krause","year":"2004","unstructured":"Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (2004) Dantrolene\u2013a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59(4):364\u2013373","journal-title":"Anaesthesia"},{"issue":"48","key":"19_CR85","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1523\/JNEUROSCI.3909-08.2008","volume":"28","author":"X. Chen","year":"2008","unstructured":"Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I (2008) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci 48:12713\u201312724","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"19_CR86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1073858404270899","volume":"11","author":"GE Stutzmann","year":"2005","unstructured":"Stutzmann GE (2005) Calcium dysregulation, IP3 signaling, and Alzheimer\u2019s disease. Neuroscientist: Rev J Bringing Neurobiol, Neurol Psychiatry 11(2):110\u2013115","journal-title":"Neuroscientist: Rev J Bringing Neurobiol, Neurol Psychiatry"},{"issue":"12","key":"19_CR87","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"Thomasin C. Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, et al (1999) Huntington\u2019s disease progression. PET and clinical observations. Brain: J Neurol 122(Pt 12):2353-2363","journal-title":"Brain"},{"issue":"21","key":"19_CR88","doi-asserted-by":"crossref","first-page":"8473","DOI":"10.1523\/JNEUROSCI.21-21-08473.2001","volume":"21","author":"He Li","year":"2001","unstructured":"Li H, Li SH, Yu ZX, Shelbourne P, Li XJ (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington\u2019s disease mice. J Neurosci: Official J Soc Neurosci 21(21):8473\u20138481","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"19_CR89","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.23866","volume":"73","author":"N\u00e9lio Gon\u00e7alves","year":"2013","unstructured":"Goncalves N, Simoes AT, Cunha RA, de Almeida LP (2013) Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Ann Neurol 73(5):655\u2013666","journal-title":"Annals of Neurology"},{"issue":"5","key":"19_CR90","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pneurobio.2007.09.002","volume":"83","author":"Jiang-Fan Chen","year":"2007","unstructured":"Chen JF, Sonsalla PK, Pedata F, et al (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and \u201cfine tuning\u201d modulation. Prog Neurobiol 83(5):310\u2013331","journal-title":"Progress in Neurobiology"},{"issue":"5","key":"19_CR91","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbamem.2010.12.001","volume":"1808","author":"Catarina V. Gomes","year":"2011","unstructured":"Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA (2011) Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 1808(5):1380\u20131399","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"issue":"5-6","key":"19_CR92","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pneurobio.2006.12.005","volume":"81","author":"P POPOLI","year":"2007","unstructured":"Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington\u2019s disease. Prog Neurobiol 81(5\u20136):331\u2013348","journal-title":"Progress in Neurobiology"},{"issue":"1-2","key":"19_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2014.01.083","volume":"101","author":"Marla Rivera-Oliver","year":"2014","unstructured":"Rivera-Oliver M, Diaz-Rios M (2014) Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 101(1\u20132):1\u20139","journal-title":"Life Sciences"},{"key":"19_CR94","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1038\/ncomms11445","volume":"7","author":"Janete Cunha-Santos","year":"2016","unstructured":"Cunha-Santos J, Duarte-Neves J, Carmona V, Guarente L, Pereira de Almeida L, Cavadas C (2016) Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway. Nat Commun 7:11445","journal-title":"Nature Communications"},{"issue":"3","key":"19_CR95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12026-014-8557-5","volume":"61","author":"Alvaro Martin","year":"2014","unstructured":"Martin A, Tegla CA, Cudrici CD, et al (2015) Role of SIRT1 in autoimmune demyelination and neurodegeneration. Immunol Res 61(3):187\u2013197","journal-title":"Immunologic Research"},{"issue":"1","key":"19_CR96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"Hyunkyung Jeong","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, et al (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159\u2013165","journal-title":"Nature Medicine"},{"key":"19_CR97","doi-asserted-by":"crossref","unstructured":"Jiang M, Wang J, Fu J, et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18(1):153\u2013158","DOI":"10.1038\/nm.2558"},{"issue":"48","key":"19_CR98","doi-asserted-by":"crossref","first-page":"17425","DOI":"10.1523\/JNEUROSCI.3958-11.2011","volume":"31","author":"H. L. Montie","year":"2011","unstructured":"Montie HL, Pestell RG, Merry DE (2011) SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci 31(48):17425\u201317436","journal-title":"Journal of Neuroscience"},{"issue":"4","key":"19_CR99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/embor.2008.31","volume":"9","author":"Takashi Torashima","year":"2008","unstructured":"Torashima T, Koyama C, Iizuka A, et al (2008) Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO reports 9(4):393\u2013399","journal-title":"EMBO reports"},{"issue":"1","key":"19_CR100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","volume":"1215","author":"Thomas Walle","year":"2011","unstructured":"Walle T (2011) Bioavailability of resveratrol. Ann NY Acad Sci 1215:9\u201315","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"11","key":"19_CR101","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awv262","volume":"138","author":"Andreia Teixeira-Castro","year":"2015","unstructured":"Teixeira-Castro A, Jalles A, Esteves S, et al (2015) Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain: J Neurol 138(Pt 11):3221\u20133237","journal-title":"Brain"},{"issue":"2","key":"19_CR102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cub.2014.11.040","volume":"25","author":"Marcus\u00a0C. Tatum","year":"2015","unstructured":"Tatum MC, Ooi FK, Chikka MR, et al (2015) Neuronal serotonin release triggers the heat shock response in C. elegans in the absence of temperature increase. Curr Biol 25(2):163\u2013174","journal-title":"Current Biology"},{"issue":"7378","key":"19_CR103","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature10671","volume":"480","author":"Philipp Koch","year":"2011","unstructured":"Koch P, Breuer P, Peitz M, et al (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480(7378):543\u2013546","journal-title":"Nature"},{"issue":"1","key":"19_CR104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12311-013-0516-5","volume":"13","author":"Ayumu Konno","year":"2013","unstructured":"Konno A, Shuvaev AN, Miyake N, Miyake K, et al (2014) Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells. Cerebellum 13(1):29\u201341","journal-title":"The Cerebellum"},{"issue":"10","key":"19_CR105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","volume":"74","author":"G. Ristori","year":"2010","unstructured":"Ristori G, Romano S, Visconti A, et al (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74(10):839\u2013845","journal-title":"Neurology"},{"issue":"10","key":"19_CR106","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"Silvia Romano","year":"2015","unstructured":"Romano S, Coarelli G, Marcotulli C, et al (2015) Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14(10):985\u2013991","journal-title":"The Lancet Neurology"},{"issue":"1","key":"19_CR107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","volume":"21","author":"Emma Hockly","year":"2006","unstructured":"Hockly E, Tse J, Barker AL, et al (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington\u2019s disease. Neurobiol Dis 21(1):228\u2013236","journal-title":"Neurobiology of Disease"},{"issue":"10","key":"19_CR108","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1523\/JNEUROSCI.5673-09.2010","volume":"30","author":"Z. Ortega","year":"2010","unstructured":"Ortega Z, Diaz-Hernandez M, Maynard CJ, Hernandez F, Dantuma NP, Lucas JJ (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin\/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 30(10):3675\u20133688","journal-title":"Journal of Neuroscience"},{"issue":"22","key":"19_CR109","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1093\/hmg\/ddp381","volume":"18","author":"Jana Boy","year":"2009","unstructured":"Boy J, Schmidt T, Wolburg H, et al (2009) Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum mol genet 18(22):4282\u20134295","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"19_CR110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jnc.13606","volume":"138","author":"Jana Schmidt","year":"2016","unstructured":"Schmidt J, Schmidt T, Golla M, et al (2016) In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. J Neurochem 138(1):150\u2013162","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"19_CR111","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01276511","volume":"102","author":"T. Sakai","year":"1995","unstructured":"Sakai T, Matsuishi T, Yamada S, Komori H, Iwashita H (1995) Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm Gen Sect 102(2):159\u2013172","journal-title":"Journal of Neural Transmission"},{"key":"19_CR112","unstructured":"Correia M, Coutinho P, Silva MC, Guimaraes J, Amado J, Matos E (1995) Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease. Rev Neurol 23(121):632\u2013634"},{"issue":"9","key":"19_CR113","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/archneur.58.9.1451","volume":"58","author":"Thorsten Schulte","year":"2001","unstructured":"Schulte T, Mattern R, Berger K, et al (2001) Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3\/Machado-Joseph disease. Arch Neurol 58(9):1451\u20131457","journal-title":"Archives of Neurology"},{"issue":"4","key":"19_CR114","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cne.901760402","volume":"176","author":"Victoria Chan-Palay","year":"1977","unstructured":"Chan-Palay V (1977) Indoleamine neurons and their processes in the normal rat brain and in chronic diet-induced thiamine deficiency demonstrated by uptake of 3H-serotonin. J Comp Neurol 176(4):467\u2013493","journal-title":"The Journal of Comparative Neurology"},{"issue":"1","key":"19_CR115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/cn400186j","volume":"5","author":"Cody J. Wenthur","year":"2013","unstructured":"Wenthur CJ, Bennett MR, Lindsley CW (2014) Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chem Neurosci 5(1):14\u201323","journal-title":"ACS Chemical Neuroscience"},{"issue":"3","key":"19_CR116","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1600-0404.2003.02132.x","volume":"107","author":"T. L. Monte","year":"2003","unstructured":"Monte TL, Rieder CR, Tort AB, et al (2003) Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 107(3):207\u2013210","journal-title":"Acta Neurologica Scandinavica"},{"issue":"10","key":"19_CR117","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archneur.1995.00540340074015","volume":"52","author":"Jau-Shin Lou","year":"1995","unstructured":"Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M (1995) Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol 52(10):982\u2013988","journal-title":"Archives of Neurology"},{"issue":"11","key":"19_CR118","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archneur.1988.00520350055016","volume":"45","author":"Paul Trouillas","year":"1988","unstructured":"Trouillas P, Brudon F, Adeleine P (1988) Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol 45(11):1217\u20131222","journal-title":"Archives of Neurology"},{"key":"19_CR119","doi-asserted-by":"crossref","unstructured":"Trouillas P, Xie J, Adeleine P (1997) Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. Prog Brain Res 114:589\u2013599","DOI":"10.1016\/S0079-6123(08)63389-0"},{"issue":"6","key":"19_CR120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archneur.1997.00550180059013","volume":"54","author":"Paul Trouillas","year":"1997","unstructured":"Trouillas P, Xie J, Adeleine P, et al (1997) Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol 54(6):749\u2013752","journal-title":"Archives of Neurology"},{"issue":"4","key":"19_CR121","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mds.870120426","volume":"12","author":"Joseph H. Friedman","year":"1997","unstructured":"Friedman JH (1997) Machado-Joseph disease\/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord: Official J Mov Disord Soc 12(4):613\u2013614","journal-title":"Movement Disorders"},{"issue":"2","key":"19_CR122","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1440-1819.2002.00952.x","volume":"56","author":"Asako Takei","year":"2002","unstructured":"Takei A, Honma S, Kawashima A, et al (2002) Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci 56(2):181\u2013185","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"1","key":"19_CR123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00002826-200401000-00005","volume":"27","author":"Asako Takei","year":"2004","unstructured":"Takei A, Fukazawa T, Hamada T, et al (2004) Effects of tandospirone on \u201c5-HT1A receptor-associated symptoms\u201d in patients with Machado-Josephe disease: an open-label study. Clin Neuropharmacol 27(1):9\u201313","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"19_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568007043482570","volume":"3","author":"Laurence Lanfumey","year":"2004","unstructured":"Lanfumey L, Hamon M (2004) 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 3(1):1\u201310","journal-title":"Current Drug Target -CNS & Neurological Disorders"},{"issue":"3","key":"19_CR125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","volume":"53","author":"Pierre Blier","year":"2003","unstructured":"Blier P, Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53(3):193\u2013203","journal-title":"Biological Psychiatry"},{"issue":"3","key":"19_CR126","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0306-4522(02)00482-7","volume":"115","author":"R Ientile","year":"2002","unstructured":"Ientile R, Caccamo D, Macaione V, Torre V, Macaione S (2002) NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells. Neuroscience 115(3):723\u2013729","journal-title":"Neuroscience"},{"issue":"6","key":"19_CR127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0404.2005.00405.x","volume":"111","author":"C.-S. Liu","year":"2005","unstructured":"Liu CS, Hsu HM, Cheng WL, Hsieh M (2005) Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy. Acta Neurol Scand 111(6):385\u2013390","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"19_CR128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/WNF.0b013e31818736a9","volume":"31","author":"Theresa A. Zesiewicz","year":"2008","unstructured":"Zesiewicz TA, Sullivan KL (2008) Treatment of ataxia and imbalance with varenicline (Chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clin Neuropharmacol 31(6):363\u2013365","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"19_CR129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0404.2008.01070.x","volume":"119","author":"T. A. Zesiewicz","year":"2009","unstructured":"Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL (2009) Treatment of imbalance with varenicline Chantix\u00ae: report of a patient with fragile X tremor\/ataxia syndrome. Acta Neurol Scand 119(2):135\u2013138","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"19_CR130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CND.0b013e3181910074","volume":"10","author":"Theresa A Zesiewicz","year":"2009","unstructured":"Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR (2009) Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 10(4):191\u2013193","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"8","key":"19_CR131","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","volume":"78","author":"T. A. Zesiewicz","year":"2012","unstructured":"Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL (2012) A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78(8):545\u2013550","journal-title":"Neurology"},{"key":"19_CR132","unstructured":"Goodwin FK (2003) Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 64(Suppl 5):18\u201324"},{"issue":"1","key":"19_CR133","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00023210-200620010-00003","volume":"20","author":"Daniel Lin","year":"2006","unstructured":"Lin D, Mok H, Yatham LN (2006) Polytherapy in bipolar disorder. CNS Drugs 20(1):29\u201342","journal-title":"CNS Drugs"},{"issue":"4","key":"19_CR134","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","volume":"61","author":"Nigel I Wood","year":"2003","unstructured":"Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington\u2019s disease mutation. Brain res bull 61(4):375\u2013383","journal-title":"Brain Research Bulletin"},{"issue":"3","key":"19_CR135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuroscience.2008.06.040","volume":"155","author":"H.-L. Feng","year":"2008","unstructured":"Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155(3):567\u2013572","journal-title":"Neuroscience"},{"issue":"6","key":"19_CR136","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12311-013-0498-3","volume":"12","author":"Dan-Dan Jia","year":"2013","unstructured":"Jia DD, Zhang L, Chen Z, et al (2013) Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3beta in a SCA3 Drosophila model. Cerebellum 12(6):892\u2013901","journal-title":"The Cerebellum"},{"issue":"6","key":"19_CR137","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0708022105","volume":"105","author":"F. Fornai","year":"2008","unstructured":"Fornai F, Longone P, Cafaro L, et al (2008) Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105(6):2052\u20132057","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"19_CR138","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1371\/journal.pmed.0040182","volume":"4","author":"Kei Watase","year":"2007","unstructured":"Watase K, Gatchel JR, Sun Y, et al (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4(5):e182","journal-title":"PLoS Medicine"},{"issue":"12","key":"19_CR139","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40263-014-0200-4","volume":"28","author":"J. van Gaalen","year":"2014","unstructured":"van Gaalen J, Kerstens FG, Maas RP, Harmark L, van de Warrenburg BP (2014) Drug-induced cerebellar ataxia: a systematic review. CNS Drugs 28(12):1139\u20131153","journal-title":"CNS Drugs"},{"issue":"4","key":"19_CR140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","volume":"29","author":"Jonas Alex Morales Saute","year":"2014","unstructured":"Saute JA, Castilhos RM, Monte TL, et al (2014) A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord: Official J Mov Disord Soc","journal-title":"Movement Disorders"},{"issue":"1","key":"19_CR141","doi-asserted-by":"crossref","first-page":"e54792","DOI":"10.1371\/journal.pone.0054792","volume":"8","author":"Jiping Yi","year":"2013","unstructured":"Yi J, Zhang L, Tang B, et al (2013) Sodium valproate alleviates neurodegeneration in SCA3\/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4. PLoS ONE 8(1):e54792","journal-title":"PLoS ONE"},{"key":"19_CR142","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","volume":"26","author":"Li-Fang Lei","year":"2016","unstructured":"Lei LF, Yang GP, Wang JL, et al (2016) Safety and efficacy of valproic acid treatment in SCA3\/MJD patients. Parkinsonism Relat Disord 26:55\u201361","journal-title":"Parkinsonism & Related Disorders"},{"issue":"2","key":"19_CR143","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12311-011-0316-8","volume":"11","author":"Jonas Alex Morales Saute","year":"2011","unstructured":"Saute JA, Donis KC, Serrano-Munuera C, et al (2012) Ataxia rating scales\u2014psychometric profiles, natural history and their application in clinical trials. Cerebellum 11(2):488\u2013504","journal-title":"The Cerebellum"},{"issue":"5","key":"19_CR144","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1038\/ncpneuro0503","volume":"3","author":"Christian Kieling","year":"2007","unstructured":"Kieling C, Morales Saute JA, Jardim LB (2007) When ataxia is not just ataxia. Nat Clin Pract Neurol 3(5):E2","journal-title":"Nature Clinical Practice Neurology"}],"container-title":["Advances in Experimental Medicine and Biology","Polyglutamine Disorders"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-71779-1_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T13:51:19Z","timestamp":1570715479000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-71779-1_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319717784","9783319717791"],"references-count":144,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-71779-1_19","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}